Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)

Market Cap	3.04B
Revenue (ttm)	58.66M
Net Income (ttm)	-139.45M
Shares Out	364.59M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	360,000
Average Volume	126,400
Open	8.50
Previous Close	8.33
Day's Range	8.33 - 9.46
52-Week Range	4.28 - 39.50
Beta	n/a
RSI	43.62
Earnings Date	Aug 28, 2025

About HKG:2563

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of advanced and neoadjuvant breast cancer, advanced non-small cell lung cancer, gastric and esophageal cancer, brain metastasis, solid tumors, and glioblastoma. It is also involved in the development of Utidelone capsule that is in Phase II...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2002
• Employees: 147
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2563

Financial Performance

In 2024, HKG:2563's revenue was 71.87 million, an increase of 7.85% compared to the previous year's 66.64 million. Losses were -143.78 million, -24.19% less than in 2023.

Financial numbers in CNY